It been a while since Anteris advised the market on internal NPV calculations. With the advances made since then there must be a reasonable reduction in risk metrics. It will be very interesting to hear there next valuation.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-2
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.92 |
Change
-0.090(0.47%) |
Mkt cap ! $366.3M | |||
| Open | High | Low | Value | Volume |
| $18.82 | $19.14 | $18.80 | $115.3K | 6.061K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 75 | $19.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.14 | 100 | 1 |
View Market Depth
| Last trade - 15.19pm 05/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |